Johnson & Johnson Long Term Debt 2011-2025 | JNJ
Johnson & Johnson long term debt from 2011 to 2025. Long term debt can be defined as the sum of all long term debt fields.
- Johnson & Johnson long term debt for the quarter ending September 30, 2025 was $39.408B, a 25.95% increase year-over-year.
- Johnson & Johnson long term debt for 2024 was $30.651B, a 18.43% increase from 2023.
- Johnson & Johnson long term debt for 2023 was $25.881B, a 3.74% decline from 2022.
- Johnson & Johnson long term debt for 2022 was $26.886B, a 10.34% decline from 2021.
|
Johnson & Johnson Annual Long Term Debt (Millions of US $) |
|
|---|---|
| 2024 | $30,651 |
| 2023 | $25,881 |
| 2022 | $26,886 |
| 2021 | $29,985 |
| 2020 | $32,635 |
| 2019 | $26,494 |
| 2018 | $27,684 |
| 2017 | $30,675 |
| 2016 | $22,442 |
| 2015 | $12,857 |
| 2014 | $15,122 |
| 2013 | $13,328 |
| 2012 | $11,489 |
| 2011 | $12,969 |
| 2010 | $9,156 |
|
Johnson & Johnson Quarterly Long Term Debt (Millions of US $) |
|
|---|---|
| 2025-09-30 | $39,408 |
| 2025-06-30 | $39,235 |
| 2025-03-31 | $38,355 |
| 2024-12-31 | $30,651 |
| 2024-09-30 | $31,289 |
| 2024-06-30 | $31,636 |
| 2024-03-31 | $25,082 |
| 2023-12-31 | $25,881 |
| 2023-09-30 | $26,051 |
| 2023-06-30 | $33,901 |
| 2023-03-31 | $34,928 |
| 2022-12-31 | $26,886 |
| 2022-09-30 | $27,603 |
| 2022-06-30 | $28,292 |
| 2022-03-31 | $28,851 |
| 2021-12-31 | $29,985 |
| 2021-09-30 | $30,130 |
| 2021-06-30 | $30,310 |
| 2021-03-31 | $30,263 |
| 2020-12-31 | $32,635 |
| 2020-09-30 | $32,680 |
| 2020-06-30 | $25,062 |
| 2020-03-31 | $25,393 |
| 2019-12-31 | $26,494 |
| 2019-09-30 | $26,919 |
| 2019-06-30 | $27,699 |
| 2019-03-31 | $27,660 |
| 2018-12-31 | $27,684 |
| 2018-09-30 | $29,480 |
| 2018-06-30 | $29,405 |
| 2018-03-31 | $29,837 |
| 2017-12-31 | $30,675 |
| 2017-09-30 | $26,675 |
| 2017-06-30 | $27,363 |
| 2017-03-31 | $27,015 |
| 2016-12-31 | $22,442 |
| 2016-09-30 | $23,546 |
| 2016-06-30 | $24,535 |
| 2016-03-31 | $20,233 |
| 2015-12-31 | $12,857 |
| 2015-09-30 | $14,073 |
| 2015-06-30 | $14,085 |
| 2015-03-31 | $14,938 |
| 2014-12-31 | $15,122 |
| 2014-09-30 | $13,152 |
| 2014-06-30 | $13,303 |
| 2014-03-31 | $13,343 |
| 2013-12-31 | $13,328 |
| 2013-09-30 | $9,748 |
| 2013-06-30 | $9,643 |
| 2013-03-31 | $11,363 |
| 2012-12-31 | $11,489 |
| 2012-09-30 | $11,428 |
| 2012-06-30 | $11,525 |
| 2012-03-31 | $13,010 |
| 2011-12-31 | $12,969 |
| 2011-09-30 | $13,031 |
| 2011-06-30 | $13,680 |
| 2011-03-31 | $9,255 |
| 2010-12-31 | $9,156 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $449.502B | $88.821B |
| Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $873.884B | 42.04 |
| AbbVie (ABBV) | United States | $387.340B | 23.19 |
| Roche Holding AG (RHHBY) | Switzerland | $267.000B | 0.00 |
| Novartis AG (NVS) | Switzerland | $266.905B | 14.15 |
| Merck (MRK) | United States | $214.149B | 9.97 |
| Novo Nordisk (NVO) | Denmark | $203.961B | 11.96 |
| Pfizer (PFE) | United States | $138.902B | 7.63 |
| Sanofi (SNY) | France | $121.941B | 11.71 |
| Bayer (BAYRY) | Germany | $29.748B | 5.61 |
| Innoviva (INVA) | United States | $1.315B | 7.81 |